Moreover, HGF was also found to induce resistance to sunitinib [41], ATE684 (a selective ALK inhibitor) [42], vemurafenib (the BRAF inhibitor, in BRAF-mutant melanoma) [43, 44], and lapatinib (a dual HER2 and EGFR tyrosine kinase inhibitor) [45]. Here, HGF is linked to melanoma.